doi: 10.1016/j.ajoc.2025.102367
Analytical data Specifications, verified
Addictive things including sugar decrease these areas sensitivity to naturally occurring dopamine
Critical Price Increases (December 2025 - March 2026): Ingredient Price Increase Primary Use Thiocolchicide 106% Muscle relaxant Glycerin 64% Solvent, excipient Nimesulide 53% Pain relief Deflazacort 50% Steroid Clobetasol Propionate 47% Skin treatment Amoxicillin Trihydrate 45% Antibiotic Paracetamol 26% Fever, pain Diclofenac Sodium 25-30% Anti-inflammatory Ciprofloxacin 20-30% Antibiotic Solvents (IPA, Acetone) 20-30% Manufacturing Multiple Factors Driving Crisis: Rupee depreciation against US dollar Petroleum-linked solvent costs (oil at $115/barrel) Container shortages and vessel delays from China Opportunistic pricing by some suppliers Industry Response: The Federation of Pharma Entrepreneurs has formally requested NPPA intervention, seeking permission for price hikes under DPCO 2013 Para 19
Why 68% of prior authorizations get denied on first submission Analysis of 2024-2025 Express Scripts prior authorization outcomes for Wegovy shows a 32% approval rate on first submission (Feldman et al., JAMA Network Open 2025)
4A and 4B), div-1(RNAi) partially suppressed the germline tumor formation of glp-1(oz112gf) mutants (28% reduction) (Fig
